Characteristics | Total N (%) | AL n (%) | MV n (%) | p-value* |
---|---|---|---|---|
Enrolled | 1480 (100.0) | 738 (100.0) | 742 (100.0) | Â |
Completed the trial and received prophylaxis | 1242 (84) | 607 (82) | 635 (86) | P = 0.081 |
Lost to follow up | 157 (11) | 79 (11) | 78 (11) | P = 0.786 |
 Received drugs at baseline | 37/157 (24) | 18/79 (23) | 19/79 (24) |  |
 Received drugs at least 1 month | 54/157 (34) | 25 /79 (32) | 29/79 (37) |  |
 Received drugs at least 2 months | 66/157 (42) | 36/79 (46) | 30 (38) |  |
Discontinued taking drug | 73 (5) | 48 (7) | 25 (3) | P = 0.005 |
 Did not receive drug for a month | 5/73 (7) | 4/48 (8) | 1/25 (4) |  |
 Received drug for at least 1 month | 58/73 (79) | 35/48 (73) | 23/25 (92) |  |
 Received drug for at least 2 months | 8/73 (11) | 7/48 (15) | 1/25 (4) |  |
 Received drug for at least 3 months | 2/73 (3) | 2/48 (4) | 0 |  |
Pregnancy | 8 (0.5) | 4 (0.5) | 4 (0.5) | Â |